Vittal Vasista - 30 Aug 2022 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
Chief Financial Officer
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Issuer symbol
RGNX
Transactions as of
30 Aug 2022
Net transactions value
-$72,573
Form type
4
Filing time
31 Aug 2022, 18:01:54 UTC
Previous filing
08 Aug 2022
Next filing
05 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Sale $72,573 -2,400 -1.7% $30.24 135,160 30 Aug 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $30.04 to $30.63. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.